Andrew Wiemer, Ph.D.

Dr. Andrew J. Wiemer is a Professor in the Department of Pharmaceutical Sciences at the University of Connecticut. His research focuses on conceptual and data-driven approaches to immune-based cancer therapeutics, integrating molecular mechanisms, metabolic pathways, and therapeutic design to guide the discovery of next-generation immunotherapies. He earned a B.S. in Biology from the University of Notre Dame and a Ph.D. in Molecular & Cellular Biology from the University of Iowa, where he developed inhibitors of geranylgeranyl diphosphate synthase, and completed postdoctoral research at the University of Wisconsin–Madison studying T cell adhesion and migration. His work has been supported by the NIH, the American Cancer Society, the American Association of Colleges of Pharmacy, and the Frasch Foundation for Chemical Research.